Seminars in Oncology
Volume 33, Issue 1 , Pages 98-105 , February 2006

Pulmonary Toxicity of Chemotherapy

  • Mark Meadors
    • ,
  • Justin Floyd
    • ,
  • Michael C. Perry

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael C. Perry, MD, FACP, University of Missouri-Columbia, Ellis Fischel Cancer Center, 115 Business Loop 70 W, Columbia, MO 65203

References 

  1. Kreisman H , Wolkove N . Pulmonary toxicity of antineoplastic therapy . Semin Oncol . 1992;19:508–520
  2. Hinson JM , Mckibben AW . Chemotherapy-associated lung injury . In:  Perry MC editors. Chemotherapy Source Book . (ed 3). Baltimore, MD: Williams & Wilkins; 2001;p. 468–476
  3. Abid SH , Malhotra V , Perry MC . Radiation-induced and chemotherapy-induced pulmonary injury . Curr Opin Oncol . 2001;13:242–248
  4. Sleijfer S . Bleomycin-induced pneumonitis . Chest . 2001;120:617–624
  5. Sikic BI . Biochemical and cellular determinants of bleomycin cytotoxicity . Cancer Surv . 1986;5:81–91
  6. Fennell DA , Rudd RM . Pulmonary toxicity and cancer treatment . Hosp Med . 2004;65:462–464
  7. Luedke D , McLaughlin T , Daughaday C , et al.   Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression . Cancer . 1985;55:542
  8. Rivera MP , Kris MG , Gralla RJ , et al.   Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy . Am J Clin Oncol . 1995;18:245–250
  9. Chang AY , Kuebler JP , Pandya KJ , et al.   Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids . Cancer . 1986;57:2285–2290
  10. Sheldon R , Slaughter D . A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma . Cancer . 1986;58:1428–1436
  11. Rosenow EC , Pisano RJ . Adverse effects of drugs on the lungs . Contemp Intern Med . 1991;3:25–34
  12. Hilliquin P , Renoux M , Perrot S , et al.   Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis . Br J Rheumatol . 1996;35:441–445
  13. St Clair EW , Rice JR , Snyder R . Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis . Arch Intern Med . 1985;145:2035
  14. Golden MR , Katz RS , Balk RA , et al.   The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis . J Rheumatol . 1995;22:1043–1047
  15. Hassell A , Dawes P . Serious problems with methotrexate . Br J Rheumatol . 1994;33:1001–1002
  16. Carroll GJ , Thomas R , Phatouros CC , et al.   Incidence, prevalence, and possible risk factors for pneumonitis with rheumatoid arthritis receiving methotrexate . J Rheumatol . 1994;21:51–54
  17. Rosenow EC . Drug induced pulmonary disease . Dis Mon . 1994;40:253–310
  18. Patel M , Ezzat W , Pauw KL , et al.   Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside . Eur J Haematol . 2001;67:318–321
  19. Battistini E , Dini G , Savioli C , et al.   Bronchiolitis obliterans organizing pneumonia in three children with acute leukemias treated with cytosine arabinoside and anthracyclines . Eur Respir J . 1997;10:1187–1190
  20. Helman DL , Byrd JC , Ales NC , et al.   Fludarabine-related pulmonary toxicity (A distinct clinical entity in chronic lymphoproliferative syndromes) . Chest . 2002;122:785–790
  21. Roychowdhury DF , Cassidy CA , Peterson P , et al.   A report on serious pulmonary toxicity associated with gemcitabine-based therapy . Invest New Drugs . 2002;20:311–315
  22. Kouroussis C , Mavroudis D , Kakolyris S , et al.   High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer (Results of a dose-finding study) . Lung Cancer . 2004;44:363–368
  23. Frieberg JW , Neuberg D , Kim H , et al.   Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease (Unacceptable acute pulmonary toxicity) . Cancer . 2003;98:978–982
  24. Oliner H , Schwartz R , Rubio F , et al.   Interstitial pulmonary fibrosis following bulsulfan therapy . Am J Med . 1961;31:134–139
  25. Hankins DG , Sanders S , MacDonald FM , et al.   Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard . Chest . 1978;73:415–416
  26. Rubio F . Possible pulmonary effects of alkylating agents . N Engl J Med . 1972;287:1150–1151
  27. Mohr M , Kingreen D , Ruhl H , et al.   Interstitial lung disease—An underdiagnosed side effect of chlorambucil? . Ann Hematol . 1993;67:305–307
  28. Akasheh MS , Freytes CO , Vesloe DH . Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation . Bone Marrow Transplant . 2000;26:1107–1109
  29. Cao T , Negrin R , Stockerl-Goldstein K , et al.   Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation . Biol Blood Marrow Transplant . 2000;6:387–394
  30. Chap L , Shpiner R , Levine M , et al.   Pulmonary toxicity of high-dose chemotherapy for breast cancer (A non-invasive approach to diagnosis and treatment) . Bone Marrow Transplant . 1997;20:1063–1067
  31. Kalaycioglu M , Kavuru M , Tuason L , et al.   Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU) . Chest . 1995;107:482–487
  32. Alessandrino EP , Bernasconi P , Colombo A , et al.   Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies . Bone Marrow Transplant . 2000;25:309–313
  33. O’Driscoll BR , Hasleton PS , Taylor PM , et al.   Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood . N Engl J Med . 1990;323:378–382
  34. Mahmood T , Mudad R . Pulmonary toxicity secondary to procarbazine . Am J Clin Oncol . 2002;25:187–188
  35. Rowinsky EK , Donehower RC . Paclitaxel (Taxol) . N Engl J Med . 1995;332:1004–1014
  36. Ramanathan RK , Reddy VV , Holbert JM , et al.   Pulmonary infiltrates following administration of paclitaxel . Chest . 1996;110:289–292
  37. Merad M , Cesne AL , Baldeyrou P , et al.   Docetaxel and interstitial pulmonary injury . Ann Oncol . 1997;8:191–194
  38. Dunsford ML , Mead GM , Bateman AC , et al.   Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma . Ann Oncol . 1999;10:943–947
  39. Rouzaud P , Estivals M , Pujazon M , et al.   Respiratory complications of the vinorelbine-mitomycin combination . Rev Mal Resp . 1999;16:81–84
  40. Johnson DH , Fehrenbacher L , Novotny W , et al.   Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer . J Clin Oncol . 2004;22:2184–2191
  41. Burton C , Kaczmarski R , Mohamed R . Interstitial pneumonitis related to rituximab therapy . N Engl J Med . 2004;26:2690–2691
  42. Swords R , Power D , Fay M , et al.   Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP) . Am J Hem . 2004;77:103–104
  43. Leon RJ , Gonsalvo A , Salas R , et al.   Rituximab-induced acute pulmonary fibrosis . Mayo Clin Proc . 2004;79:949–953
  44. ImClone Pharmaceutical Corporation . Erbitux (cetuximab) prescribing information . 2004; Brauchburg, NJ, February
  45. Novartis Pharmaceuticals Corporation . Gleevec (imatinib mesylate) prescribing information . 2001; East Hanover, NJ, May
  46. Goldsby R , Pulsipher M , Adams R , et al.   Unexpected pleural effusions in 3 pediatric patients treated with STI-571 . J Pediatr Hematol Oncol . 2002;24:694–695 (letter)
  47. Rosado MR , Donna E , Ahn YS . Imatinib mesylate-induce interstitial pneumonitis . J Clin Oncol . 2003;21:3171–3173
  48. Ma CX , Hobday TJ , Jett JR . Imatinib mesylate-induced interstitial pneumonitis . Mayo Clin Proc . 2003;78:1578–1579
  49. Isshiki I , Yamaguchi K , Okamoto S . Interstitial pneumonitis during imatinib therapy . Br J Haematol . 2004;125:420
  50. Bergeron A , Bergot E , Vilela G , et al.   Hypersensitivity pneumonitis related to imatinib mesylate . J Clin Oncol . 2002;20:4270–4271
  51. Astra Zeneca Pharmaceuticals Corporation . Iressa (gefitnib) prescribing information . 2005; Wilmington, DE, January
  52. Evans TL . Highlights from the tenth world conference on lung cancer . Oncologist . 2004;9:232–238
  53. Genetech Pharmaceuticals Corporation . Tarceva (erlotinib) prescribing information . 2004; San Francisco, CA, November
  54. Zitnik RJ , Matthay RA . Drug-induced lung disease . In:  Schwarz MI ,  King TE editor. Interstitial Lung Disease . Hamilton, Canada: Decker; 1998;p. 423–449
  55. Gertz MA , Lacy MQ , Bjornsson J , et al.   Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis (A report and review of growth factor-induced pulmonary toxicity) . J Hematother Stem Cell Res . 2000;9:635–643
  56. Matthews JH . Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease (Possible synergy) . Lancet . 1993;342:988–989
  57. Saxman SB , Nichols CR , Einhorn LH . Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor . Chest . 1997;111:657–660
  58. Eisenbeis CF , Winn D , Poelman S , et al.   A case of pulmonary toxicity associated with G-CSF and doxorubicin administration . Ann Hematol . 2001;80:121–123
  59. Yokose N , Ogata K , Tamura H , et al.   Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin’s lymphoma . Br J Cancer . 1998;77:2286–2290
  60. Briasoulis E , Froudarakis M , Milionis HJ , et al.   Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support . Respiration . 2000;67:680–683
  61. Belch A , Kouroukis C , Crump M , et al.   Phase II trial of bortezomib in mantle cell lymphoma . Blood . 2004;104:175a; (abstr 608)
  62. Sandhu H , Barnes P , Hernandez P . Hydroxyurea-induced hypersensitivity pneumonitis (A case report and literature review) . Can Respir J . 2000;7:491–495
  63. In:  Chu E ,  DeVita VT editor. Physicians’ Cancer Chemotherapy Drug Manual 2004 . Sudbury, MA: Jones & Bartlett; 2003;
  64. Madarnas Y , Webster P , Shorter A , et al.   Irinotecan-associated pulmonary toxicity . Anti-Cancer Drugs . 2000;11:709–713

PII: S0093-7754(05)00435-5

doi: 10.1053/j.seminoncol.2005.11.005

Seminars in Oncology
Volume 33, Issue 1 , Pages 98-105 , February 2006

Article Tools